IgA Nephropathy Pipeline Dynamics Signal Further Treatment Evolution on the Horizon
Spherix Global Insights’ fourth annual IgAN patient chart audit reveals continued shifts in the IgAN treatment paradigm with the use...
Spherix Global Insights’ fourth annual IgAN patient chart audit reveals continued shifts in the IgAN treatment paradigm with the use...
A chart review completed by Spherix Global Insights shows that more nephrologists are using SGLT2 inhibitors to treat patients with...
Analysis of 1,052 chronic kidney disease non-dialysis patient charts reveals continuous growth in SGLT2 inhibitor use and expanding opportunities for...
EVRENZO’s advantages of being first-to-market and possessing a broader label are likely to be key factors influencing VAFSEO uptake, according...
PHILADELPHIA — Results of a survey conducted in the U.S. and abroad showed that most nephrologists remain wary about prescribing...
According to Spherix Global Insights, US nephrologists have expressed a high level of enthusiasm for Novartis’ iptacopan and atrasentan, as...
According to Spherix Global Insights and EU5 nephrologists are anticipating a more dynamic and competitive HIF-PH inhibitor market Exton, PA,...
According to Spherix Global Insights, the latest findings from RealTime Dynamix™: Renal Anemia report indicate that the more familiar nephrologists...
Spherix Global Insights announces the release of its third annual US IgAN patient chart audit showing major shifts in IgAN...
The path to approval was long and winding for a new class of medicines called hypoxia-inducible factor prolyl hydroxylase (HIF-PH)...
Surveyed nephrologists indicate enormous unmet need for new drugs to treat hyperphosphatemia and anticipate early adoption if the product is...
110 U.S. nephrologists provided immediate feedback regarding GSK’s newly approved HIF-PH inhibitor – the first approved in the United States...